Lexaria Bioscience Corp.
LEXX
$1.35
-$0.34-20.12%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 20.00% | 21.55% | 173.62% | 8.11% | 625.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.00% | 21.55% | 173.62% | 8.11% | 625.00% |
| Cost of Revenue | -- | -43.75% | -- | -- | -- |
| Gross Profit | 20.00% | 23.69% | 173.62% | 29.23% | 747.95% |
| SG&A Expenses | 118.46% | 29.19% | 134.70% | 51.94% | -11.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 259.78% | 122.77% | 114.74% | -26.29% | -39.50% |
| Operating Income | -311.83% | -136.21% | -112.94% | 27.41% | 49.53% |
| Income Before Tax | -316.27% | -128.41% | -75.07% | 25.14% | 50.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -316.27% | -128.41% | -75.07% | 25.14% | 50.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 18.75% | -49.12% | -81.44% | -78.51% | -74.40% |
| Net Income | -317.74% | -129.26% | -76.29% | 24.87% | 49.97% |
| EBIT | -311.83% | -136.21% | -112.94% | 27.41% | 49.53% |
| EBITDA | -321.52% | -139.33% | -127.35% | 27.28% | 49.80% |
| EPS Basic | -156.88% | -24.48% | 9.03% | 65.07% | 72.35% |
| Normalized Basic EPS | -154.55% | -29.94% | -12.01% | 65.85% | 71.54% |
| EPS Diluted | -156.88% | -24.48% | 9.03% | 65.07% | 72.35% |
| Normalized Diluted EPS | -154.55% | -29.94% | -12.01% | 65.85% | 71.54% |
| Average Basic Shares Outstanding | 62.67% | 84.15% | 93.78% | 115.11% | 80.90% |
| Average Diluted Shares Outstanding | 62.67% | 84.15% | 93.78% | 115.11% | 80.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |